(Q26827714)

English

Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy

scientific article

In more languages

Statements

scholarly article

1 reference

4 references

12 March 2019

25 June 2019

17 June 2019

13 December 2020

systematic review

1 reference

based on heuristic

inferred from title

Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy (English)

1 reference

3 references

12 March 2019

25 June 2019

17 June 2019

1 reference

13 December 2020

systematic review

1 reference

based on heuristic

inferred from title

author name string

Elizabeth A. Brezinski

1

1 reference

April W. Armstrong

2

1 reference

language of work or name

1 reference

publication date

2012

1 reference

11 April 2012

4 references

12 March 2019

25 June 2019

17 June 2019

13 December 2020

5 references

12 March 2019

25 June 2019

17 June 2019

13 December 2020

7

1 reference

4

1 reference

e33486

1 reference

copyright license

Creative Commons Attribution 4.0 International

4 references

Europe PubMed Central

12 March 2019

Europe PubMed Central

25 June 2019

Europe PubMed Central

17 June 2019

Europe PubMed Central

13 December 2020

copyright status

0 references

on focus list of Wikimedia project

0 references

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3324468

7 April 2017

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3324468

7 April 2017

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3324468

7 April 2017

Interleukin-12 and the regulation of innate resistance and adaptive immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3324468

7 April 2017

The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3324468

28 September 2017

A new era in the management of psoriasis? The biologics: facts and controversies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3324468

28 September 2017

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3324468

28 September 2017

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3324468

28 September 2017

Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3324468

28 September 2017

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3324468

28 September 2017

Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3324468

28 September 2017

The role of T cells in psoriasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3324468

28 September 2017

Recent developments in the understanding of the pathogenesis of psoriasis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3324468

28 September 2017

Consensus Conference on cyclosporin A for psoriasis February 1992

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3324468

28 September 2017

Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3324468

31 May 2018

Psoriasis causes as much disability as other major medical diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3324468

31 May 2018

Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0033486

21 January 2018

Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0033486

21 January 2018

Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0033486

21 January 2018

Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0033486

21 January 2018

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0033486

21 January 2018

The safety and efficacy of high-dose alefacept compared with a loading dose of alefacept in patients with chronic plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0033486

21 January 2018

Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0033486

21 January 2018

An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0033486

21 January 2018

Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0033486

21 January 2018

A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3324468

28 November 2018

The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3324468

28 November 2018

A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22509259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunologic targets in psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22509259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etanercept as monotherapy in patients with psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22509259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Remittive effects of intramuscular alefacept in psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22509259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Psoriasis Is Common, Carries a Substantial Burden Even When Not Extensive, and Is Associated with Widespread Treatment Dissatisfaction

1 reference

https://pubmed.ncbi.nlm.nih.gov/22509259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/22509259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction

1 reference

https://pubmed.ncbi.nlm.nih.gov/22509259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22509259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22509259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22509259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

What have we learned in dermatology from the biologic therapies?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22509259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22509259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22509259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept

1 reference

https://pubmed.ncbi.nlm.nih.gov/22509259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The safety profile and sustained remission associated with response to multiple courses of intramuscular alefacept for treatment of chronic plaque psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22509259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22509259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22509259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of psoriasis with different dosage regimens of etanercept: preliminary results from the Tαranta Plastic Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/22509259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0033486

0 references

2012PLoSO...733486B

0 references

PMC publication ID

1 reference

PubMed publication ID

1 reference

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q26827714&oldid=1965587341"